@Article{Krawczyk2010,
journal="Kardiochirurgia i Torakochirurgia Polska/Polish Journal of Thoracic and Cardiovascular Surgery",
issn="1731-5530",
volume="7",
number="4",
year="2010",
title="TORAKOCHIRURGIADo NSCLC patients become sensitive to second-line erlotinib treatment after previous radiotherapy?",
abstract="  Background  : Erlotinib is an EGFR tyrosine kinase inhibitor (EGFR-TKI) that has shown activity in recurrent NSCLC. One could speculate that sensitivity to erlotinib is dependent on the activated form of EGFR gene mutation in tumour cells. The radiation-induced activation of the EGFR pathway and EGFR gene mutation in cancer cells could arouse the response to EGFR-TKI agents.    Aim  : The aim of the study was to evaluate the effectiveness of erlotinib in second- and third-line therapy according to the type of first-line therapy.    Material and methods  : 102 patients with recurrent NSCLC, who had erlotinib administered in second- and third-line therapy, were divided into two groups: group A – included patients treated first-line with a combination of thoracic radiotherapy and cisplatin-based chemotherapy (n = 40); group B – patients treated with chemotherapy alone (n = 62). The efficacy of erlotinib was analysed based on chi-square, Cox logistic regression and Kaplan-Meier tests.    Results  : Disease control and survival longer than 6 months during erlotinib administration were observed significantly more frequently in patients from Group A than from Group B (p < 0.05 and p < 0.005, respectively). Median time of overall survival was 16 months for Group A and only 5 months for Group B. Moreover, probability of survival was significantly higher in Group A than in Group B (p < 0.005, HR = 2.179, 95% CI: 1.339-3.546). Based on the Cox regression model, among 6 other prognostic factors, no application of radiotherapy in first-line treatment had a significant impact on the reduction of overall survival (p < 0.005, HR = 2.636, 95% CI: 1.385-5.015).    Conclusions  : Our observations indicate that application of radiotherapy in first-line treatment has predictive rather than prognostic value for the efficacy of erlotinib second- or third-line therapy.",
author="Krawczyk, Paweł
and Kowalski, Dariusz M.
and Wojas-Krawczyk, Kamila
and Krzakowski, Maciej
and Milanowski, Janusz",
pages="411--414",
url="https://www.termedia.pl/TORAKOCHIRURGIA-Do-NSCLC-patients-become-sensitive-to-second-line-erlotinib-treatment-after-previous-radiotherapy-,40,16007,1,1.html"
}